๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 41 Nanjing 23 Guangzhou 18 Shanghai 18 Wuhan 14
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking University First Hospital12 AstraZeneca4 Pfizer3 Peking Union Medical College Hospital3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences2
Site location
Beijing41 Nanjing23 Guangzhou18 Shanghai18 Wuhan14
All 59 locations
Target enrolment
to

Trials with a site in Beijing

41 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer
NCT07468396Prostate Cancer
Gan & Lee Pharmaceuticals.
Phase 1
65
Beijing
2026-04-30
Not yet open
Darolutamide ยฑ ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer
NCT07476677Prostate Cancer
DrugDarolutamide
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Beijing
2026-04-01
Recruiting
A Study of DXC014 in Patients With Advanced Solid Tumors.
NCT07177937Small Cell Lung Cancer, Melanoma, Prostate Cancer, Other Advanced Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
150
Beijing, Changsha, Nanchang, Qingdao, Hangzhou
2026-03-03
Recruiting
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
NCT07339267Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsASP5541·Prednisone
Astellas Pharma Global Development, Inc.
Phase 1
12
Beijing
2026-01-20
Recruiting
A Phase I Trial of A-CAR032 in Participants With mCRPC
NCT07344311Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer
Shanghai AbelZeta Ltd.
Phase 1
27
Beijing, Wuhan, Xuzhou, Hangzhou
2026-01-13
Not yet open
Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT07381582Prostate Cancer
Peking Union Medical College Hospital
Phase EARLY_PHASE1
15
Beijing, Mianyang
2026-01-01
Active, closed
Clinically Actionable Tumor-Associated Antigens in Prostate Cancer
NCT07597369Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Cancer (mCRPC)
Peking University First Hospital
Observational
1,600
Beijing
2026-01-01
Not yet open
Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
NCT07282197Prostate Cancer
DrugDarolutamide
Peking University First Hospital
Phase 2
40
Beijing
2026-01
Recruiting
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
NCT07192614Prostate Cancer
AstraZeneca
Phase 1/2
52
Beijing, Chengdu, Guangzhou, Nanjing
2025-09-30
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naรฏve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsMevrometostat·Xtandi·Enzalutamide
Pfizer
Phase 3
1,000
Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Wuhan, Changsha, Huai'an
2025-09-28
Not yet open
Enhanced Recovery After Surgery (ERAS) Pathway in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy
NCT05576766Prostate Cancer, Robot-Assisted Laparoscopic Radical Prostatectomy, Enhanced Recovery After Surgery (ERAS) Protocol, Prehabilitation
Peking University First Hospital
Not applicable
54
Beijing
2025-09
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/Prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua
2025-08-06
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277Prostate Cancer
DrugsAAA817·ARPI
Novartis Pharmaceuticals
Phase 3
940
Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing
2025-07-01
Recruiting
A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults
NCT07149831Prostate Cancer
DrugFlotufolastat F-18
Sinotau Pharmaceutical Group
Phase 1
6
Beijing
2025-06-07
Recruiting
Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer
NCT07015138Prostate Cancer, Oligometastatic Prostate Cancer
Peking University First Hospital
Not applicable
390
Beijing
2025-06-01
Recruiting
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
NCT06926283Prostate Cancer, Other Solid Tumors, Ewing Sarcoma
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
110
Changsha, Hangzhou, Beijing
2025-05-15
Active, closed
The Value of Dual-parametric Magnetic Resonance Combined With Regional Saturation Biopsy in Patients With Suspected Prostate Cancer
NCT06824259Prostate Cancer
Peking University First Hospital
Not applicable
400
Beijing
2025-05-14
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisone·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Beijing, Chongqing, Fuzhou, Guangzhou, Zhuhai, Nanning, Zhengzhou, Wuhan
2025-05-13
Not yet open
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
NCT06922903Prostate Cancer
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
240
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Recruiting
Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cancer
NCT07115277Prostate Cancer
DrugFlotufolastat F-18
Sinotau Pharmaceutical Group
Not applicable
121
Beijing
2025-03-14
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670Prostate Cancer
DrugAAA817
Novartis Pharmaceuticals
Phase 2/3
443
Fuzhou, Wuhan, Nanjing, Shenyang, Xian, Chengdu, Beijing, Guangzhou
2025-02-27
Recruiting
Optimizing Prostate Biopsy Schemes in Men With Multiple MRI Visible Lesions
NCT06841211Prostate Cancer
Peking University First Hospital
Not applicable
572
Beijing
2025-02-01
Recruiting
Evaluation of Targeted Biopsy Plus Sextant Biopsy in Diagnosis of Prostate Cancer
NCT06684652Prostate Cancer
Peking University First Hospital
Not applicable
300
Beijing
2024-12-01
Recruiting
Evaluation of Perilesional Biopsy in Diagnosis of Prostate Cancer
NCT06482645Prostate Cancer
Peking University First Hospital
Not applicable
640
Beijing
2024-07-01
Not yet open
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study
NCT06435702Prostate Cancer
Peking University Third Hospital
Observational
108
Beijing
2024-06-01
Recruiting
Comparison of MRI Artificial Intelligence-guided cTB Versus Routine cTB in Prostate Cancer Diagnosis
NCT06392737Prostate Cancer
Peking University First Hospital
Not applicable
360
Beijing
2024-05-01
Recruiting
Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing
NCT07319923Prostate Cancer, Community-based Screening
Peking University First Hospital
Observational
3,000
Beijing
2024-01-01
Recruiting
The Development and Validation of MRI-AI-based Predictive Models for csPCa
NCT06842264Prostate Cancer
Peking University First Hospital
Observational
3,000
Beijing
2024-01-01
Recruiting
Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
NCT06139575Prostate Cancer
Bivision Pharmaceuticals, Inc.
Phase 1/2
90
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Wuxi
2023-12-22
Recruiting
CART-PSMA Cells for Advanced Prostate Cancer
NCT05656573Prostate Cancer
Nova Therapeutics LLC
Phase 1
20
Beijing
2023-03-01
Recruiting
68Ga-RM26-RGD PET/CT Imaging in the GRPR and ฮฑvฮฒ3 Positive Tumor Patients
NCT05549024Breast Cancer, Prostate Cancer, Brain Tumor, PET/CT Imaging
DrugFluorodeoxyglucose
Peking Union Medical College Hospital
Phase EARLY_PHASE1
90
Beijing
2022-08-16
Recruiting
68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients
NCT05324332Prostate Cancer
Drug68Ga-PSMA-11
Peking Union Medical College Hospital
Not applicable
50
Beijing
2022-04-15
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
DrugsCapivasertib·Docetaxel
AstraZeneca
Phase 3
1,035
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jiaxing
2022-03-25
Active, closed
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622Prostate Cancer
DrugsTalazoparib·Enzalutamide
Pfizer
Phase 3
599
Hefei, Beijing, Lanzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2021-05-12
Recruiting
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
NCT05183074Prostate Cancer, Radiotherapy Side Effect, Magnetic Resonance-linac, Stereotactic Ablative RT
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2021-02-01
Active, closed
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
DrugsSaruparib·Camizestrant·Datopotamab Deruxtecan·Trastuzumab deruxtecan
AstraZeneca
Phase 1/2
702
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Harbin, Jining
2020-11-12
Active, closed
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
DrugsPF-07220060·Midazolam
Pfizer
Phase 2
362
Beijing, Zhengzhou, Wuhan, Xiโ€™an, Hangzhou
2020-09-23
Recruiting
MR Microstructural Imaging for Prostate Cancer Diagnosis
NCT07249281Prostate Cancer, Diffusion MRI
First Affiliated Hospital of Zhejiang University
Observational
2,000
Beijing, Zhengzhou, Nanjing, Dalian, Hangzhou
2020-09-01
Recruiting
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04221542Prostate Cancer
DrugsXaluritamig·Abiraterone·Enzalutamide
Amgen
Phase 1
479
Beijing, Guangzhou, Nanchang, Shanghai, Hangzhou, Nanjing, Wenzhou
2020-03-04
Recruiting
Adjuvant Chemotherapy for High Malignant Prostate Cancer
NCT06864533Prostate Cancer, Radiation Therapy, Chemotherapy, Gleason Score
DrugDocetaxel
Peking University First Hospital
Observational
315
Beijing, Shenzhen, Baoding
2019-09-01
Active, closed
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
NCT02489318Prostate Cancer
DrugApalutamide
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai
2015-11-27
Rows per page Showing 1–41 of 41
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 41 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

27 of the 41 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 41 studies
PhaseStudiesRecruitingShare
Not applicable10824.4%
Phase 18719.5%
Phase 38419.5%
Observational6414.6%
Phase 1/2327.3%
Phase 2307.3%
Phase EARLY_PHASE1214.9%
Phase 2/3112.4%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Peking University First Hospital128
AstraZeneca42
Peking Union Medical College Hospital32
Pfizer31
Cancer Institute and Hospital, Chinese Academy of Medical Sciences21
Hangzhou DAC Biotechnology Co., Ltd.22
Novartis Pharmaceuticals22
Sinotau Pharmaceutical Group22
Amgen11
Aragon Pharmaceuticals, Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.